Gleason Score and Grade Group: Complete Guide to Understanding Your Prostate Biopsy Result

Receiving a diagnosis of prostate cancer is a difficult time, filled with emotions and questions. The medical report you receive, called a histopathology report, contains complex terms that can add an extra layer of confusion and anxiety. One of the most important indicators on this report is the Gleason score .

This article, created specifically for patients and their families, aims to translate medical language into a simple and clear guide. We will explore what the Gleason score means, how it has evolved into the modern Grade Group system , and most importantly, what implications this score has for treatment options.

What is the Gleason Score? A Look Under the Microscope

After your urologist performs a prostate biopsy, the tissue samples are sent to a specialist doctor called a pathologist. He or she examines the cells under a microscope to determine whether they are cancerous and, if so, how aggressive they appear. Aggressiveness is determined by how much the cancer cells differ from normal, healthy prostate cells.

The Gleason scoring system, developed in the 1960s, is based on five cell growth patterns, scored from 1 to 5.

Grade 1 and 2: The cells closely resemble normal tissue and are no longer used in current practice to describe cancer.
Grade 3: The cells are starting to look abnormal, but are still forming glandular structures.
Grade 4: The cells are clearly abnormal, poorly defined, and beginning to fuse.
Grade 5: The cells are very irregular (poorly differentiated) and hardly resemble normal cells at all, indicating the most aggressive form.

To calculate the Gleason score, the pathologist identifies two predominant patterns in the tissue sample:

First number: Represents the grade of cancer cells occupying the largest area (primary pattern).
Second number: Represents the degree of the second most common pattern (the secondary pattern).

These two numbers are added together to get the final Gleason score, which ranges from 6 to 10. For example: 3 + 4 = 7 .

From Gleason Score to Grade Group (ISUP): A Modern and Clearer Classification

Although useful, the Gleason score can be confusing. For example, a score of 7 could mean either 3+4 or 4+3. Although the sum is the same, the prognosis is different because the order of the numbers matters. A score of 4+3 is more aggressive than a score of 3+4 because the predominant pattern (the first number) is more aggressive.

To simplify and provide a clearer picture of risk, the International Society of Urological Pathology (ISUP) introduced a more modern system called Grade Group in 2014. This system, also adopted by international guidelines such as NCCN, groups Gleason scores into five distinct categories, making it much more intuitive.

Here is the correspondence between the two systems:

Grade Group 1: Corresponds to a Gleason score of 6 (3+3) .
- What it means: A low-grade, very slow-growing cancer. It is considered the least dangerous.
Grade Group 2: Corresponds to a Gleason score of 7 (3+4) .
- What it means: Intermediate-grade cancer with a favorable prognosis. Most of the cells are slow-growing.
Grade Group 3: Corresponds to a Gleason score of 7 (4+3) .
- What it means: Intermediate-grade cancer with a poor prognosis. Most of the cells are more aggressive and have moderate growth.
Grade Group 4: Corresponds to a Gleason score of 8 .
- What it means: Highly aggressive cancer. The cells have rapid growth and an increased potential to spread.
Grade Group 5: Corresponds to a Gleason score of 9 or 10 .
- What it means: The most aggressive type of cancer. These tumors are the most likely to grow and spread quickly.

What does Grade Group mean for your treatment plan?

Grade Group is one of the three main pillars (along with tumor stage – T and PSA level ) that define the risk category of prostate cancer: low, intermediate or high risk. This classification is essential to decide the best therapeutic strategy.

Grade Group 1 (Low Risk)
For patients with low-grade tumors, which grow very slowly, immediate treatment is not always necessary. The preferred option in these cases, according to international guidelines, is active surveillance . This involves careful monitoring of the disease through periodic PSA tests, digital rectal exams and repeated biopsies, intervening with curative treatment (surgery or radiotherapy) only if signs of disease progression appear.

Grade Group 2 and 3 (Intermediate Risk)
Here, the treatment decision becomes more complex.

For Grade Group 2 (Gleason 3+4) , considered intermediate-favorable risk, active surveillance may still be a viable option for certain carefully selected patients.
For Grade Group 3 (Gleason 4+3) , considered intermediate-risk, the risk of progression is higher, and definitive treatments are usually recommended.
The main options include radical prostatectomy (surgical removal of the prostate) and radiotherapy . In some cases of intermediate-risk, radiotherapy may be combined with short-term (4-6 months) hormonal therapy (ADT) to increase the effectiveness of the treatment.

Grade Group 4 and 5 (High and Very High Risk)
These tumors are aggressive and require an intensive treatment plan to maximize the chances of cure. Options include:

Radical prostatectomy , often followed by radiotherapy and/or hormonal therapy, depending on the final results of the surgical piece.
Radiotherapy combined with long-term hormonal therapy (1-3 years), as this combination has been shown to be superior to monotherapy. In selected cases, chemotherapy may also be added.

Beyond the Gleason Score: Other Risk Assessment Tools

Modern medicine is constantly evolving, and today, in addition to Gleason score, T stage, and PSA, there are advanced tools that can provide additional information about the aggressiveness of the tumor. These include:

Genomic tests: These analyze the activity of certain genes in tumor cells to more accurately predict the likelihood of cancer spreading. Tests like Decipher or Prolaris can help the doctor and patient make more informed decisions, such as whether adding hormone therapy to radiation therapy is truly necessary.
Advanced imaging (multiparametric MRI): A high-quality MRI can provide details about the location and extent of the tumor within the prostate, helping to better plan treatment.

Conclusion: The Gleason score is a map, not a sentence

It is essential to remember that the Gleason score or Grade Group is a crucial, but not the only, component of your diagnosis. It must be interpreted in the context of your clinical stage, PSA level, overall health, and personal preferences.

Understanding these numbers transforms you from a passive patient to an active partner in your own healing process. We encourage you to talk openly with your doctor, ask questions, and explore all of your options.

Do you need a second opinion?

Navigating a cancer diagnosis can be overwhelming. If you want further validation of your histopathology result and recommended treatment plan, the Oncoexpertai.com platform is here for you. Upload your biopsy report for advanced analysis, powered by artificial intelligence and reviewed by oncology experts, to get the clarity and confidence you need.

If you just want a completely free opinion without uploading any medical documents, use one of the 2 orange boxes “Talk to Dr. Onisim” or green “Message to Dr. Onisim”

Disclaimer: The information presented in this article is for informational and educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult your doctor with any questions you may have regarding a medical condition.

Bibliography

European Association of Urology. EAU Guidelines on Prostate Cancer. EAU Guidelines Office; 2026.
Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. Journal of Urology. 2023;210(1):54–63. doi: 10.1097/JU.0000000000003492
Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. Journal of Urology. 2022;208(1):10–18. doi: 10.1097/JU.0000000000002757
WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2022.
van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology. 2020;44(8):e87–e99. doi: 10.1097/PAS.0000000000001497
Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(9):1119–1134. doi: 10.1016/j.annonc.2020.06.011
Eggener SE, Rumble RB, Armstrong AJ, et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology. 2020;38(13):1474–1494. doi: 10.1200/JCO.19.02768

Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI

Onisim Florin

Login